Cargando…
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related...
Autores principales: | Baek, Dong Won, Chae, Yee Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yeungnam University College of Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688779/ https://www.ncbi.nlm.nih.gov/pubmed/33752275 http://dx.doi.org/10.12701/yujm.2021.00899 |
Ejemplares similares
-
Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer
por: Okawa, Sachi, et al.
Publicado: (2019) -
A Rare Association of Autoimmune Hemolytic Anemia with Gastric Adenocarcinoma
por: Agrawal, Kavita, et al.
Publicado: (2017) -
Autoimmune Hemolytic Anemia with Autoimmune Hypothyroidism: A Case Report
por: Karki, Prakriti, et al.
Publicado: (2023) -
Thymoma with Autoimmune Hemolytic Anemia
por: Suzuki, Kensuke, et al.
Publicado: (2014) -
Hemolytic Anemias: Autoimmune and Beyond
por: Krishnadasan, Ravi
Publicado: (2021)